A tolerability profile in clinical trials with children and adults with EPI due to CF1
Treatment-emergent adverse events (AEs) occurring in at least 2 ZENPEP-treated patients (Study 1)1
This table depicts treatment-emergent AEs in patients with EPI due to CF aged ≥7 years that occurred in at least 2 patients (≥6%) during treament and crossover treatment periods with ZENPEP in Study 1.1